urea/悪性腫瘍

1. FIELD OF THE INVENTION The present invention relates to novel carbamates, ureas, and pharmaceutically acceptable salts thereof; compositions comprising the carbamate, urea, or a pharmaceutically acceptable salt thereof; and methods for treating or preventing cancer, inflammation, or a viral

RELATED APPLICATION This application is related to: United Kingdom patent application number 1320729.5 filed 25 Nov. 2013, the contents of which are incorporated herein by reference in their entirety. TECHNICAL FIELD The present invention pertains generally to the field of therapeutic compounds.

RELATED APPLICATION This application is related to: United Kingdom patent application number 1320729.5 filed 25 Nov. 2013, the contents of which are incorporated herein by reference in their entirety. TECHNICAL FIELD The present invention pertains generally to the field of therapeutic

CROSS-REFERENCE TO RELATED APPLICATION This application claims the benefit of Korean Patent Application No. 10-2006-079561, filed Aug. 22, 2006 with the Korean Intellectual Property Office, the disclosure of which is incorporated herein in its entirety by reference. BACKGROUND OF THE INVENTION 1.

FIELD OF THE INVENTION This invention relates to novel compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g.,

FIELD OF THE INVENTION This invention relates to novel compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g.,

FIELD OF THE INVENTION This invention relates to novel hydroxy methyl phenyl pyrazolyl urea compounds, pharmaceutical compositions containing such compounds and the use of these compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in

FIELD OF THE INVENTION This invention relates to novel compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g.,

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 14, 2009, is named 22035111.txt, and is 13,485 bytes in size. FIELD OF THE INVENTION The present

TECHNICAL FIELD OF THE INVENTION The present invention relates to compounds useful for inhibiting enzymes that maintain and repair the integrity of genetic material. More particularly, the present invention relates to a series of aryl- and heteroaryl-substituted urea compounds, methods of making the

DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: DECP_063_01US_SeqList_ST25.txt, date recorded: Mar. 15,

FIELD OF THE INVENTION Disclosed are compounds which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by

BACKGROUND OF THE INVENTION The Raf/MEK/ERK pathway is critical for cell survival, growth, proliferation and tumorigenesis. See, e.g., Nanxin Li, et al., Current Opinion in Investigational Drugs. Vol. 8, No. 6 (2007): 452-456. Raf kinases exist as three isoforms, A-Raf, B-Raf and C-Raf. Among the

PRIORITY CLAIM TO RELATED APPLICATIONS This application is a U.S. national stage filing under 35 U.S.C. .sctn. 371 from International Application No. PCT/CN2017/076265, filed on 10 Mar. 2017, and published as WO2017/152874 on 14 Sep. 2017, which claims the benefit under 35 U.S.C. 119 to Chinese

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage of International Patent Application No. PCT/JP2016/002557 filed May 26, 2016, which claims priority from Japanese Patent Application No. 2015-107227 filed May 27, 2015, the disclosures of each of which are incorporated